[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616651":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":10,"maxAge":10,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":44,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Toripalimab group",null,[12],"Drug: Toripalimab",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Toripalimab","A humanized IgG4 monoclonal antibody against programmed cell death protein 1 (PD-1). The recommended dosage is 240 mg administered intravenously on Day 1 of each 3-week cycle (q3w). Treatment continues until disease progression, unacceptable toxicity, death, withdrawal of consent, or investigator decision. It is used in combination with chemotherapy (etoposide and platinum-based drugs) as per routine clinical practice.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Zhengfei Zhu, PhD","CONTACT","+8618017312901","fuscczzf@163.com",{"type":26,"investigatorFullName":27,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhengfei Zhu","Professor","100616651","real-world-study-of-toripalimab-in-extensive-stage-small-cell-lung-cancer-100616651",false,"NCT07308379","Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer","A Prospective, Observational, Multi-Center, Real-World Study of Toripalimab Injection in First-Line Treatment of Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Voluntarily participate and sign the informed consent form.\n* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC);\n* Scheduled to receive Toripalimab as first-line treatment;\n* Availability of traceable medical history records during the treatment period.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Known allergic to recombinant humanized anti-PD-1 monoclonal antibody drugs or their components；\n* Any other condition deemed by the investigator as unsuitable for inclusion in the study.","ALL",{"count":38,"type":39},1200,"ESTIMATED","OBSERVATIONAL","This is a prospective, observational, multi-center, real-world study evaluating the effectiveness and safety of Toripalimab (a PD-1 inhibitor) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The primary objective is to assess real-world progression-free survival (rwPFS). Secondary objectives include evaluating real-world objective response rate (rwORR), disease control rate (rwDCR), overall survival (rwOS), and safety. Approximately 1200 patients from multiple centers in China will be enrolled and followed according to routine clinical practice. Data will be collected from medical records and follow-up visits.",[43,16],"SCLC, Extensive Stage",[45,16,46],"Extensive stage SCLC","Real-World Study","NOT_YET_RECRUITING","2025-12-15",{"date":50,"type":51},"2025-12-29","ACTUAL",{"date":53,"type":39},"2026-02",{"date":55,"type":39},"2028-08",{"name":5,"class":6}]